Evolution of RAS Mutational Status in Liquid Biopsies During First-Line Chemotherapy for Metastatic Colorectal Cancer

Treatment options for patients with metastatic colorectal cancer (mCRC) are limited. This particularly affects the largest group of patients with RAS mutations, who are considered ineligible for therapy with antiEGFR antibodies. In this liquid biopsy-based study, we performed the first in-depth anal...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Front Oncol
Main Authors: Klein-Scory, Susanne, Wahner, Ingo, Maslova, Marina, Al-Sewaidi, Yosef, Pohl, Michael, Mika, Thomas, Ladigan, Swetlana, Schroers, Roland, Baraniskin, Alexander
Format: Artigo
Jezik:Inglês
Izdano: Frontiers Media S.A. 2020
Teme:
Oncology
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7378792/
https://ncbi.nlm.nih.gov/pubmed/32766143
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.01115
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki